Avizakimab, formerly known as BOS161721, represents a novel medicinal approach to treating autoimmune conditions . This monoclonal substance selectively targets IL-18 , a vital cytokine implicated in the https://kaitlynecrp190218.blog-gold.com/58698167/avizakimab-a-detailed-exploration-into-bos161721-s-potential